Elevated IGF‑binding protein‑3 (IGFBP‑3) means more IGF‑1/2 are bound, reducing free, active IGF levels. It can reflect changes in growth‑hormone activity, hormone therapies, liver function alterations, or be associated with certain tumors or metabolic states. Interpretation depends on symptoms and accompanying IGF‑1/GH tests; review results with your clinician for appropriate follow‑up and testing.

IGFBP‑3 (insulin‑like growth factor binding protein‑3) is the main carrier of circulating IGF‑I and IGF‑II, extending their half‑life and regulating tissue availability and receptor access. By sequestering or releasing IGFs it modulates growth, metabolism and cell proliferation. IGFBP‑3 also has IGF‑independent actions — it can bind cell surface receptors or translocate to the nucleus to influence apoptosis and cell‑cycle arrest.

IGFBP‑3 (insulin‑like growth factor binding protein‑3) is measured alongside IGF‑1 to assess growth hormone (GH) status. Compare values to age‑ and sex‑specific reference ranges. Low IGFBP‑3 suggests GH deficiency, malnutrition, or liver disease; high levels can occur with GH excess, pregnancy, or certain medications. Interpret alongside IGF‑1, clinical signs, and medication/lab factors; confirm with endocrine evaluation.

Low IGFBP‑3 means reduced levels of the main carrier protein for IGF‑1/2. It often reflects growth‑hormone deficiency, poor nutrition, liver disease, chronic illness, or hypopituitarism. Low IGFBP‑3 alters IGF bioavailability, can contribute to growth failure in children, and warrants further evaluation (GH/IGF‑1 testing, nutritional and liver assessment) to find and treat the underlying cause.

High IGF-1 levels (often from excess growth hormone) cause tissue overgrowth—children may develop gigantism; adults can develop acromegaly with enlarged hands/feet, facial changes, joint pain, headaches and vision problems. Elevated IGF-1 promotes insulin resistance, increasing diabetes and cardiovascular risk, and raises cell proliferation linked to higher risk of certain cancers. Evaluation and treatment address the underlying pituitary cause.

IGF‑binding protein commonly measured is IGFBP‑3. Adult reference values are roughly 3.3–7.8 µg/mL (3.3–7.8 mg/L), though exact ranges vary by age, sex and laboratory assay. Pediatric, elderly and pregnancy ranges differ. Because assays and units differ between labs, interpret results using the specific laboratory’s reference interval and discuss abnormal results with your clinician.